Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.
Results of the 3½-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment [...]

Medgenics (AIM:MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial.
The landmark Phase I/II clinical trial of Medgenics’ EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway. The current trial is designed to assess the safety and efficacy of the EPODURE Biopump in providing [...]

Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS® (peginterferon alfa-2a (40KD)) and COPEGUS® (ribavirin) to 72 weeks, according to new studies being presented at AASLD this week in San Francisco.
“Seeking solutions for difficult-to-treat hepatitis C with the currently-available agents is a priority,” [...]

A new, independently-conducted study being presented at AASLD shows that PEGASYS® (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan Safety Tolerability Study
Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M. Migliavacca Center for Liver Disease [...]

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS - News) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting [...]

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study [...]

Schering-Plough Corporation (NYSE: SGP - News) today reported that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon and ribavirin markedly increased sustained virologic response (SVR) rates with 28 weeks of therapy and nearly doubled SVR with 48 weeks of therapy [...]

Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at [...]

A new, independently-conducted study being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) shows that PEGASYS® (peginterferon alfa-2a) treatment regimens result in higher sustained virological response (SVR) rates for hepatitis C patients as compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan [...]

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS - News) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting [...]